Navigation Links
Potential blood test for chronic sinusitis identified
Date:4/14/2008

A protein profile has been identified in the blood of chronic sinusitis sufferers that may enable physicians to objectively diagnosis and treat the disease, researchers say.

They used a sophisticated research tool that rapidly assesses expression of large numbers of proteins and found among 96 chronic sinusitis patients a profile missing in 38 healthy controls.

We can diagnose this disease with a totally objective test that does not depend on symptoms or observations, says Dr. Stilianos E. Kountakis, vice chair of the Department of Otolaryngology-Head and Neck Surgery in the Medical College of Georgia School of Medicine. He is corresponding author on the study published in the March/April issue of American Journal of Rhinology.

Diagnosing this chronically irritating disease, characterized by dripping noses, sinus pressure, congestion and difficulty breathing, currently is rather subjective. Patients talk about symptoms and doctors look at their sinuses with an endoscope and probably a computerized tomography scan. (O)verall management of (chronic sinusitis) is still hampered by the lack of quantifiable, molecular and genetic markers to aid in screening, researchers write.

To be classified chronic, the misery has to continue for at least 12 weeks. Causes include bacterial infections, respiratory inflammation, sinus polyps and mucosal disease. Some causes, such as polyps and asthma, have a genetic predisposition. You may have a bacterial infections, allergies, mechanical problems, Dr. Kountakis says. There are numerous genes that control respiratory function. Any of these things can go wrong to predispose the patient to develop chronic sinusitis.

Treating it isnt much more straightforward. Surgery can help correct anatomical causes such as deviated septums or polyps. However, there are no FDA-aproved drugs specifically to treat chronic sinusitis. Instead, physicians use drugs that treat symptoms: steroid sprays for inflammation, mucus thinners, saline irrigation, etc. Its difficult to show drugs are effective because its difficult to group patients together and measure their disease, says Dr. Kountakis.

He hopes further studies will enable both, revealing signature protein profiles for different types of chronic sinusitis as well as the degree of disease. The bottom line is we want to group patients according to their disease rather than just the general term chronic sinusitis, Dr. Kountakis says. If we can find a way to classify patients, group them together based on the specific disease they have, maybe we can get better outcomes and treat patients with better efficiency.

These objective measures should allow monitoring the effectiveness of current therapies and objectively reviewing new ones, he says.

In fact, even getting a handle on disease incidence is tough. The National Health Interview Survey, based on self-reports, says 14 to 16 percent of people in the United States have chronic sinusitis. A population-based study of the Olmsted County, Minnesota published in 2004 in Archives of Otolaryngology-Head & Neck Surgery put the incidence at 2 percent.

For this study, researchers analyzed protein expression in the blood using surface enhanced laser desorption ionization time-of-flight mass spectroscopy or SELDI-TOF-MS. The test is about 88 percent accurate.


'/>"/>

Contact: Toni Baker
tbaker@mcg.edu
706-721-4412
Medical College of Georgia
Source:Eurekalert  

Related medicine news :

1. Medical errors cost US $8.8B, result in 238,337 potentially preventable deaths: HealthGrades study
2. Stem cell research leads to potential new therapy for rare blood disorder
3. New research shows benefits of ultrasound contrast agents outweigh potential risk to heart patients
4. Angina drug potentially useful against heart rhythm disorders
5. Neuronal regulators offer potential targets for cancer
6. Companies Not Fully Tapping Potential of Onsite Health Centers
7. Study Finds Potential Cause of Age-Related Macular Degeneration
8. More Clinical Data Required to Support European Approval of Desvenlafaxine as a Potential Treatment for Vasomotor Symptoms
9. New potential treatment for muscular dystrophy appears to be safe
10. Regenstrief Institute tapped by CDC to combat potentially catastrophic disease outbreaks
11. Research shows promise for potential new gene therapy strategy for muscle-wasting diseases
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Potential blood test for chronic sinusitis identified
(Date:6/24/2016)... ... 24, 2016 , ... People across the U.S. are sharpening their pencils and ... essay contest in which patients and their families pay tribute to a genetic counselor ... National Society of Genetic Counselors (NSGC) Annual Education Conference (AEC) this September. , ...
(Date:6/24/2016)... ... June 24, 2016 , ... ... Investment Group (TGIG), has initiated cultivation and processing operations at its production facility, ... Pahrump, Nevada. , Puradigm is the manufacturer of a complete system of proactive ...
(Date:6/24/2016)... ... June 24, 2016 , ... Venture Construction Group (VCG) sponsors Luke’s ... June 20th at the Woodmont Country Club at 1201 Rockville Pike, Rockville, Maryland, 20852. ... helping service members that have been wounded in battle and their families. Venture Construction ...
(Date:6/24/2016)... ... 2016 , ... Finally, a bruise cream that really works. Originally designed ... into the post-surgical treatment plans of a variety of other procedures including, but not ... effective for bruising and causes a rapid resolution of bruising and inflammatory changes compared ...
(Date:6/24/2016)... , ... June 24, 2016 , ... Today, InhaleLabs.com ... the ingestion of their medication by matching users with high quality water pipes within ... pieces with no commitment. , Inhale was founded by two brothers, Nick and Mike ...
Breaking Medicine News(10 mins):
(Date:6/24/2016)... 2016 Dehaier Medical Systems Ltd. (NASDAQ: ... markets and sells medical devices and wearable sleep respiratory ... strategic cooperation agreement with Hongyuan Supply Chain Management Co., ... June 20, 2016, to develop Dehaier,s new Internet medical ... Dehaier will leverage Hongyuan Supply Chain,s sales platform to ...
(Date:6/24/2016)... 2016 According to a new ... Pen Needles, Safety Pen Needles), Needle Length (4mm, 5mm, ... Mode of Purchase (Retail, Non-Retail) - Trends & Global ... the market for the forecast period of 2016 to ... Billion by 2021 from USD 1.65 Billion in 2016, ...
(Date:6/24/2016)... 2016  Arkis BioSciences, a leading innovator in ... durable cerebrospinal fluid treatments, today announced it has ... is led by Innova Memphis, followed by Angel ... investors.  Arkis, new financing will accelerate the commercialization ... release of its in-licensed Endexo® technology. ...
Breaking Medicine Technology: